|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/22 AIM ImmunoTech Inc. 10-K 12/31/21 90:9.3M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.77M
2: EX-4.23 Instrument Defining the Rights of Security Holders HTML 36K
3: EX-10.78 Material Contract HTML 59K
4: EX-10.79 Material Contract HTML 48K
5: EX-10.80 Material Contract HTML 26K
6: EX-10.81 Material Contract HTML 113K
7: EX-10.82 Material Contract HTML 58K
8: EX-21 Subsidiaries List HTML 24K
9: EX-23.1 Consent of Expert or Counsel HTML 24K
10: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
13: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
19: R1 Cover HTML 94K
20: R2 Consolidated Balance Sheets HTML 122K
21: R3 Consolidated Balance Sheets (Parenthetical) HTML 39K
22: R4 Consolidated Statement of Comprehensive Loss HTML 91K
23: R5 Consolidated Statement of Changes in Stockholders' HTML 61K
Equity
24: R6 Consolidated Statements of Cash Flows HTML 128K
25: R7 Business HTML 35K
26: R8 Summary of Significant Accounting Policies HTML 68K
27: R9 Marketable Securities HTML 72K
28: R10 Patents, Trademark Rights HTML 38K
29: R11 Accrued Expenses HTML 33K
30: R12 Stockholders? Equity HTML 383K
31: R13 Segment and Related Information HTML 31K
32: R14 Research, Consulting and Supply Agreements HTML 37K
33: R15 401(k) Plan HTML 29K
34: R16 Employment Agreements HTML 57K
35: R17 Leases HTML 49K
36: R18 Income Taxes (FASB ASC 740 Income Taxes) HTML 61K
37: R19 Note Payable HTML 43K
38: R20 Certain Relationships and Related Transactions HTML 29K
39: R21 Concentrations of Risk HTML 30K
40: R22 Fair Value HTML 146K
41: R23 Financing Obligation Arising from Sale Leaseback HTML 32K
Transaction
42: R24 Subsequent Events HTML 33K
43: R25 Summary of Significant Accounting Policies HTML 99K
(Policies)
44: R26 Summary of Significant Accounting Policies HTML 32K
(Tables)
45: R27 Marketable Securities (Tables) HTML 72K
46: R28 Patents, Trademark Rights (Tables) HTML 38K
47: R29 Accrued Expenses (Tables) HTML 31K
48: R30 Stockholders? Equity (Tables) HTML 314K
49: R31 Leases (Tables) HTML 30K
50: R32 Income Taxes (FASB ASC 740 Income Taxes) (Tables) HTML 49K
51: R33 Fair Value (Tables) HTML 130K
52: R34 Business (Details Narrative) HTML 25K
53: R35 Schedule of Property and Equipment (Details) HTML 39K
54: R36 Summary of Significant Accounting Policies HTML 47K
(Details Narrative)
55: R37 Schedule of Available for Sale (Details) HTML 68K
56: R38 Schedule of Equity Securities (Details) HTML 30K
57: R39 Marketable Securities (Details Narrative) HTML 30K
58: R40 Schedule of Patents, Trademark Rights (Details) HTML 33K
59: R41 Schedule of Amortization of Patents and Trademarks HTML 40K
(Details)
60: R42 Patents, Trademark Rights (Details Narrative) HTML 27K
61: R43 Schedule of Accrued Expenses (Details) HTML 35K
62: R44 Schedule of Options and Equity Estimated Based on HTML 37K
Weighted Average Assumptions (Details)
63: R45 Schedule of Stock Option Activity (Details) HTML 142K
64: R46 Schedule of Unvested Stock Option Activity HTML 75K
(Details)
65: R47 Schedule of Warrants Outstanding and Exercisable HTML 69K
(Details)
66: R48 Stockholders? Equity (Details Narrative) HTML 243K
67: R49 Research, Consulting and Supply Agreements HTML 36K
(Details Narrative)
68: R50 401(k) Plan (Details Narrative) HTML 31K
69: R51 Employment Agreements (Details Narrative) HTML 57K
70: R52 Schedule of Operating lease Future Payments HTML 38K
(Details)
71: R53 Leases (Details Narrative) HTML 65K
72: R54 Schedule of Components of Net Deferred Tax Assets HTML 48K
and Liabilities (Details)
73: R55 Schedule of Effective Tax Rate and Statutory Tax HTML 51K
Rate (Details)
74: R56 Income Taxes (FASB ASC 740 Income Taxes) (Details HTML 44K
Narrative)
75: R57 Note Payable (Details Narrative) HTML 67K
76: R58 Certain Relationships and Related Transactions HTML 33K
(Details Narrative)
77: R59 Schedule of Assumptions to Estimate Fair Value of HTML 87K
Warrants (Details)
78: R60 Schedule of Range of Probabilities (Details) HTML 31K
79: R61 Schedule of Assets and Liabilities Measured at HTML 38K
Fair Value on a Recurring Basis (Details)
80: R62 Schedule of Changes in Level 3 Liabilities HTML 30K
Measured at Fair Value on a Recurring Basis
(Details)
81: R63 Schedule of Assets and Liabilities Measured at HTML 39K
Fair Value on a NonRecurring Basis (Details)
82: R64 Schedule of Assets and Liabilities Measured at HTML 33K
Fair Value on a NonRecurring Basis (Details)
(Parenthetical)
83: R65 Fair Value (Details Narrative) HTML 36K
84: R66 Financing Obligation Arising from Sale Leaseback HTML 45K
Transaction (Details Narrative)
85: R67 Subsequent Events (Details Narrative) HTML 41K
88: XML IDEA XML File -- Filing Summary XML 150K
86: XML XBRL Instance -- form10-k_htm XML 2.11M
87: EXCEL IDEA Workbook of Financial Reports XLSX 103K
15: EX-101.CAL XBRL Calculations -- aim-20211231_cal XML 195K
16: EX-101.DEF XBRL Definitions -- aim-20211231_def XML 724K
17: EX-101.LAB XBRL Labels -- aim-20211231_lab XML 1.31M
18: EX-101.PRE XBRL Presentations -- aim-20211231_pre XML 984K
14: EX-101.SCH XBRL Schema -- aim-20211231 XSD 194K
89: JSON XBRL Instance as JSON Data -- MetaLinks 430± 591K
90: ZIP XBRL Zipped Folder -- 0001493152-22-008324-xbrl Zip 355K
Exhibit 10.82
| EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT |  |
| THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL | |
AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
PHARMACEUTICS INTERNATIONAL, INC. SERVICES CHANGE ORDER
Initiation Date 2/28/2022 |
Project Number: 27AIM01 |
Change Order Number: 1 |
AIM ImmunoTech Inc. Contact: Victoria Scott, Director of Quality & Regulatory Affairs
Corporate Address: 2117 SW Highway 484 Corporate Phone 352-448-7797 Corporate Fax: 352-480-4620 Email: Victoria.Scott@AIMimmuno.com
Pii Contact: Luis Molina, Director, Business Management
Corporate Address: 10819 Gilroy Road Corporate Phone: 410-584-0001 Email: lmolina@pharm-int.com
| ||
| Change Order Title: Manufacture placebo feasibility batch; Method transfer for in-process assay – Ampligen sterile solution | ||
I. Change in Scope and Associated Costs
| Activity | COST | Total Cost |
AIM ImmunoTech Inc. (“Client”) has requested Pii provide method transfer services for in-process assay. AIM ImmunoTech has authorized Pii to issue this Change Order, which covers the activities/deliverables and any equipment/material listed in the following sections. |
||
Section 1: Method transfer for in-process assay.
|
$[***] | $[***] |
| Section 2: Manufacture of Placebo Feasibility cGMP Batch. |
| ● | Pii will manufacture one (1) placebo feasibility batch with NO filling and Compounding and Filtration only. |
| ○ | Tests to be performed | $[***] | $[***] |
| ■ | pH |
|||
| ■ | osmolality |
|||
| Section 3: Materials Testing Charge – Estimate only (Actuals will be billed) | ||||
| API: | ||||
| ● | Full release testing will be charged at $[***] / lot | |||
| ● | ID release at $[***] / lot | |||
| 27AIM01 CO1 | March 25, 2022 | Page 1 of 4 |
| CONFIDENTIAL |
C:
| Note: For the engineering trial mentioned in section 2, water will be used as the testing material | ||||
| Excipients: | ||||
| ● | USP/NF and EP/JP full release testing will be charged at $8,500 / lot | |||
| ● | PII will use stock excipients where applicable and may opt to charge on a per kg basis | |||
| ● | ID release at $[***] / lot | |||
| Packaging Components: | ||||
| ● | USP/NF full release testing will be charged at $[***] / lot | |||
| ● | PII will use stock components where applicable and may opt to charge on a per unit basis | |||
| ● | ID release at $[***] / lot | |||
| Note: | ||||
| ● | Any outsourced testing not conducted at Pii for API, Excipients, or Packaging Components will be invoiced as a pass through + handling costs as per the terms of the agreement. | |||
| Sub-Total: | $[***] | |||
Estimated Costs for Pass Through: (For budgeting purposes only based on 20% of subtotal; actuals will be billed as noted herein) |
$[***] | |||
In addition to the above costs:
| ● | Client shall pay to Pii upon receipt of Pii’s invoice by Client for all non-capital materials (excipients, packaging components, HPLC columns, analytical standards, microbial testing and tooling) used in the study at cost plus 10%. Pii shall obtain Client’s prior written approval for any expenditure greater than $5,000. For high priced items more than $5,000, Pii will charge cost plus 5% to Client . Pii shall invoice Client for all reasonable and normal out-of-pocket travel-related expenses, including airfare, room & board, car rental and the like, of Pii during any technology transfer phase or project update meetings requested in advance by Client. | |
| ● | Any excipients, materials or components ordered as specialized items (not standard stock items) for use in the project will be invoiced in full to Client. A handling fee will apply as noted above. Payment is due within 45 days of receipt of invoice by Client. | |
| ● | Materials Usage and Testing will be per the terms of the original agreement (“Materials Charges and Testing (Estimate Only)” of Section III: Cost) | |
| ● | Any OOS investigation and testing that is not considered to be Pii laboratory error will be billed at a rate of $300/hour. | |
| ● | Any remaining stock of specialized items ordered on behalf of Client or shipped to Pii by Client will be shipped to Client upon notification by Pii. Client will be solely responsible for cost of shipment and a shipment preparation fee of $1,500 will be applied. | |
| ● | Shipments outside of Agreement work scope will be invoiced as per the following: |
| a) | Shipment requests with three (3) day notice or more will be charged at $500 plus shipping costs and a 10% service charge on shipping. | |
| b) | Shipment requests with two (2) day notice will be charged at $1,000 plus shipping costs and a 10% service charge on shipping. | |
| c) | Shipment requests with twenty-four (24) hour notice will be charged at $1,500 plus shipping costs and a 10% service charge on shipping. |
| 27AIM01 CO1 | March 25, 2022 | Page 2 of 4 |
| CONFIDENTIAL |
C:
II. Payment Schedule
| Milestones | Activity | Amount Due |
Change Order Initiation |
Change Order Initiation (Non-refundable)- 27AIM01 CO1 – Manufacture placebo feasibility batch; Method transfer for in-process assay – Ampligen sterile solution.
Please remit payment upon receipt of Pii invoice. |
$[***] |
| Completion of Analytical Method for In-Process Assay | |||
| 1 | ● | Provision of Draft of the Method Transfer Report sent to AIM ImmunoTech, Inc. for the in-process Assay | $[***] |
| 2 | Completion of Manufacturing of Placebo Feasibility Batch
|
$[***] | |
| ● | R&D reviewed executed Feasibility Batch Record sent to AIM ImmunoTech, Inc. | ||
| Total | $$[***] | ||
| 27AIM01 CO1 | March 25, 2022 | Page 3 of 4 |
| CONFIDENTIAL |
C:
III. Signatures
This Agreement is Change Order No. 1 to Service Agreement No. 27AIM01 executed by AIM ImmunoTech Inc. and Pii dated December 22, 2020.
| Pii Signatory | Signature and Date | ||
| John Guthrie | /s/ John Guthrie | March 8, 2022 | |
| Chief Financial Officer | |||
| Client Signatory (Client Representative) | |||
| Ellen M. Lintal | /s/ Ellen M Lintal | March 8, 2022 | |
| Chief Financial Officer | |||
Purchase Order Number: __________________
(Provided by Client if necessary)
| 27AIM01 CO1 | March 25, 2022 | Page 4 of 4 |
| CONFIDENTIAL |
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/31/22 | 10-Q | ||
| 3/25/22 | ||||
| 3/8/22 | ||||
| For Period end: | 12/31/21 | |||
| 12/22/20 | 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/24 AIM ImmunoTech Inc. S-1 6:628K M2 Compliance LLC/FA 4/01/24 AIM ImmunoTech Inc. 10-K 12/31/23 84:8.7M M2 Compliance LLC/FA 3/31/23 AIM ImmunoTech Inc. 10-K 12/31/22 87:8.7M M2 Compliance LLC/FA 8/15/22 AIM ImmunoTech Inc. 10-Q 6/30/22 72:6M M2 Compliance LLC/FA 7/01/22 AIM ImmunoTech Inc. S-8 7/01/22 4:143K M2 Compliance LLC/FA 5/13/22 AIM ImmunoTech Inc. 10-Q 3/31/22 68:5.6M M2 Compliance LLC/FA |